Company: AEMD
Filing Date: 2025-08-29
Form Type: S-1/A
Source: 0001683168-25-006537
Chunk: 35

Company: AETHLON MEDICAL INC
Filing Date: 2025-08-29
Form: S-1/A
Chunk 35
---
 appropriate, consultants in order to conserve cash and resources.

We believe our employee relations
are good. None of our employees are represented by a labor union or are subject to collective-bargaining agreements.

Summary Risk Factors

Investing in our securities involves a high degree of risk. You should consider carefully the risks described below, together with all of the other information included or incorporated by reference in this prospectus, including the risks and uncertainties discussed under “Risk Factors” in our Annual Report on Form 10-K for the year ended March 31, 2025, which has been filed with the SEC and is incorporated by reference in this prospectus, as well as any updates thereto contained in subsequent filings with the SEC or any free writing prospectus, before deciding whether to purchase our securities in this offering. All of these risk factors are incorporated herein in their entirety. The risks described below and incorporated by reference are material risks currently known, expected or reasonably foreseeable by us. However, the risks described below are not the only ones that we face. Additional risks not presently known to us or that we currently deem immaterial may also affect our business, operating results, prospects or financial condition. If any of these risks actually materialize, our business, prospects, financial condition, and results of operations could be seriously harmed. This could cause the trading price of our common stock and the value of the warrants to decline, resulting in a loss of all or part of your investment.

| 16 |

Risk Factor Summary

Risks Relating to Our Financial Position and Need for Additional Capital

| · | We have a history of significant operating losses and expect continued losses for the foreseeable future.                         |
| · | We currently have no revenue streams and may not obtain future government contracts or grants.                                    |
| · | There is substantial doubt about our ability to continue operations for 12 months following our most recent financial statements. |
| · | We plan to raise capital via equity markets, but there is no assurance of success.                                                |
| · | Additional financing is essential for operations, clinical trials, regulatory approvals, and product development.                 |
| · | Equity or convertible debt financing may significantly dilute existing stockholders and impact control.                           |
| · | External economic factors, including inflation and market volatility, may impair our ability to raise capital.                    |
| · | Our status as a going concern is uncertain, which could harm our share price, credibility, and commercial relationships.          |
| · | Inability to continue as a going concern